MK0966; rofecoxib / Duration of Treatment: 24 weeks + Comparator: placebo / Duration of Treatment: 24 weeks
ApprovedTerminated 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Adenomatous Polyposis Coli
Conditions
Adenomatous Polyposis Coli
Trial Timeline
Aug 6, 2002 → Oct 11, 2004
NCT ID
NCT00140894About MK0966; rofecoxib / Duration of Treatment: 24 weeks + Comparator: placebo / Duration of Treatment: 24 weeks
MK0966; rofecoxib / Duration of Treatment: 24 weeks + Comparator: placebo / Duration of Treatment: 24 weeks is a approved stage product being developed by Merck for Adenomatous Polyposis Coli. The current trial status is terminated. This product is registered under clinical trial identifier NCT00140894. Target conditions include Adenomatous Polyposis Coli.
What happened to similar drugs?
0 of 1 similar drugs in Adenomatous Polyposis Coli were approved
Approved (0) Terminated (1) Active (0)
Hype Score Breakdown
Clinical
20
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00140894 | Approved | Terminated |
Competing Products
3 competing products in Adenomatous Polyposis Coli
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Celecoxib + Placebo | Pfizer | Phase 3 | 32 |
| Celecoxib | Pfizer | Pre-clinical | 18 |
| REC-4881 + Placebo | Recursion Pharmaceuticals | Phase 1/2 | 33 |